Claims for Patent: 8,945,551

Summary for Patent: 8,945,551

Title:	Biopolymer hybrid gel-depot delivery system
Abstract:	The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.
Inventor(s):	Mainwaring; David Edward (North Melbourne, AU), Al Kobaisi; Mohammad (Glen Iris, AU), Chua; Brendon Yew Loong (Mount Waverley, AU), Jackson; David Charles (North Balwyn, AU)
Assignee:	Polymers CRC Ltd. (AU)
Application Number:	13/382,655
Patent Claims:	1. A prolonged release and/or controlled release delivery system for delivery of a biologically active agent, the system comprising: (i) a first component comprising a biocompatible polyaminosaccharide; and (ii) a second component comprising a biocompatible phosphate or biocompatible sulphonamide compound capable of crosslinking with the first component, wherein the delivery system further comprises the biologically active agent, an aqueous insoluble alkaline earth metal phosphate, and a biocompatible glycan; wherein each of the biologically active agent, aqueous insoluble earth metal phosphate and biocompatible glycan is present in either of the first and/or second components; and wherein the % wt/wt ratio ranges of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate or biocompatible sulphonamide is from about 100:74 to about 100:184; and whereby the first and second components of the system are physically isolated and, when in use, combining of the first and second components promotes crosslinking and results in the formation of a biopolymer hybrid gel-depot including the biological active agent. 2. The delivery system according to claim 1 wherein the biocompatible polyaminosaccharide is chitosan or a salt thereof. 3. The delivery system according to claim 2 wherein the biologically active agent is conjugated to the chitosan. 4. The delivery system according to claim 1 wherein the biocompatible phosphate or sulphonamide is sodium triphosphate (TPP). 5. The delivery system according to claim 1 wherein the aqueous insoluble alkaline earth metal phosphate is hydroxyapatite. 6. The delivery system according to claim 1 wherein the biocompatible glycan is selected from chondroitin sulphate, sodium hyaluronate, and carboxymethyl cellulose. 7. The delivery system according to claim 1 wherein the biocompatible glycan is a proteoglycan. 8. The delivery system according to claim 1 wherein the biological active agent is selected from the group consisting of insulin, cortisol, estrogen or growth hormone, infliximab, adalimumab, nituximab, alemtuzumab, daclizumab, basiliximab etanercept and LHRH. 9. The delivery system according to claim 1 wherein the biopolymer hybrid gel-depot including the biological active agent has a Young's modulus in the range of about 20 to 60 kPa. 10. The delivery system according to claim 1 wherein the biopolymer hybrid gel-depot including the biological active agent has a compressive modulus in the range of about 100 kPa to 500 kPa. 11. A method of forming a prolonged release and/or controlled release biopolymer hybrid gel-depot including a biologically active agent, said method comprising: (i) providing a first component comprising a biocompatible polyaminosaccharide, and a second component comprising a biocompatible phosphate and/or sulphonamide compound capable of crosslinking with the first component, (a) wherein the first and/or second component further comprises the biologically active agent; and (b) wherein the first and/or second component also comprises: (i) an aqueous insoluble alkaline earth metal phosphate; and/or (ii) a biocompatible glycan and/or proteoglycan wherein the % wt/wt ratio ranges of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate or biocompatible sulphonamide is from about 100:74 to about 100:184; and (ii) combining the first and second components for a time and under conditions to promote crosslinking and to form a biopolymer hybrid gel-depot including the biologically active agent. 12. A biopolymer hybrid gel-depot comprising: (i) a biocompatible polyaminosaccharide; (ii) a biocompatible phosphate and/or sulphonamide substantially crosslinked to (i); (iii) an aqueous insoluble alkaline earth metal phosphate; (iv) a biocompatible proteoglycan; and (v) a biologically active agent, wherein the % wt/wt ratio ranges of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate or biocompatible sulphonamide is from about 100:74 to about 100:184. 13. A biopolymer hybrid gel-depot comprising: (i) chitosan (or a suitably functionalised derivative thereof); (ii) tripolyphosphate substantially crosslinked to (i); (iii) hydroxyapatite; (iv) chondroitin sulphate; and (v) a biologically active agent wherein the % wt/wt ratio ranges of: the chitosan to the hydroxyapatite is from about 40:1 to about 10:1; and the chitosan to the tripolyphosphate is from about 100:74 to about 100:184. 14. A method of delivering a biologically active agent to a subject including the step of administering: (i) a first component comprising a biocompatible polyaminosaccharide; and (ii) a second component comprising a biocompatible phosphate and/or sulphonamide compound capable of crosslinking with the first component, wherein (a) the first and/or second component further comprises the biologically active agent; and (b) the first and/or second compounds also comprises: an aqueous insoluble alkaline earth metal phosphate; and/or (ii) a biocompatible glycan and/or proteoglycan; wherein the % wt/wt ratio ranges of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate and/or biocompatible sulphonamide is from about 100:74 to about 100:184; and whereby the first and second components are simultaneously or sequentially injected at the same site. 15. A method of delivering a biologically active agent to a subject including the step of implanting a biopolymer hybrid gel-depot comprising: (i) a biocompatible polyaminosaccharide; (ii) a biocompatible phosphate and/or sulphonamide substantially crosslinked to (i); (iii) an aqueous insoluble alkaline earth metal phosphate; (iv) a biocompatible glycan and/or proteoglycan; and (v) a biologically active agent wherein the % wt/wt ratio ranges of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate and/or biocompatible sulphonamide is from about 100:74 to about 100:184. 16. A prolonged release and/or controlled release delivery system for delivery of a biologically active agent, the system comprising: (i) a first component comprising a biocompatible polyaminosaccharide, the biologically active agent, and an aqueous insoluble alkaline earth metal phosphate; and (ii) a second component comprising a biocompatible phosphate or biocompatible sulphonamide compound capable of crosslinking with the first component, and a biocompatible glycan; wherein the % wt/wt ratio ranges of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate or biocompatible sulphonamide is from about 100:74 to about 100:184; and whereby the first and second components of the system are physically isolated and, when in use, combining of the first and second components promotes crosslinking and results in the formation of a biopolymer hybrid gel-depot including the biological active agent. 17. A prolonged release and/or controlled release delivery system for delivery of a biologically active agent to a subject, the system comprising: (i) a first component comprising a biocompatible polyaminosaccharide; and (ii) a second component comprising a biocompatible phosphate or biocompatible sulphonamide compound capable of crosslinking with the first component; wherein the delivery system further comprises the biologically active agent, an aqueous insoluble alkaline earth metal phosphate and a biocompatible glycan; wherein each of the biologically active agent, aqueous insoluble earth metal phosphate and biocompatible glycan is present in either of the first and/or second components; and wherein the % wt/wt ratio range of: the biocompatible polyaminosaccharide to the aqueous insoluble alkaline earth metal phosphate is from about 40:1 to about 10:1; and the biocompatible polyaminosaccharide to the biocompatible phosphate or biocompatible sulphonamide is from about 100:74 to about 100:184; and whereby the first and second components of the system are physically isolated and, when injected into the subject result in the formation of a biopolymer hybrid gel-depot including the biological active agent in the subject, wherein the biopolymer hybrid gel-depot including the biological active agent has a compressive modulus in the range of about 100 kPa to 500 kPa. 18. The delivery system according to claim 17, wherein the biocompatible polyaminosaccharide is chitosan or a salt thereof. 19. The delivery system according to claim 17, wherein the biologically active agent is conjugated to the chitosan. 20. The delivery system according to claim 17, wherein the biocompatible phosphate or biocompatible sulphonamide is sodium triphosphate (TPP). 21. The delivery system according to claim 17, wherein the insoluble alkaline earth metal phosphate is hydroxyapatite. 22. The delivery system according to claim 17, wherein the biocompatible glycan is selected from the group consisting of chondroitin sulphate, sodium hyaluronate, and carboxymethyl cellulose. 23. The delivery system according to claim 22, wherein the biocompatible glycan is chondroitin sulphate. 24. The delivery system according to claim 17, wherein the biopolymer hybrid gel-depot including the biological active agent has a Young's modulus in the range of about 20 to 60 kPa.

Details for Patent 8,945,551

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2029-07-09
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2029-07-09
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2029-07-09
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2029-07-09
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2029-07-09
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2029-07-09